Max Healthcare
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Max Healthcare's recent management commentary highlights a robust growth trajectory driven by aggressive capacity expansion and strategic acquisitions, particularly the integration of Kalinga Hospital and new projects in Pune. Despite a strong 16% YoY revenue growth in the core hospital business, the company faces short-term margin pressures due to the commissioning of new facilities and integration costs. Vista's financial outlook reflects these dynamics, projecting continued revenue growth supported by a significant expansion pipeline of over 4,000 beds in the next 4-5 years, although margins may remain under pressure in the near term. The healthcare sector's stable pricing power and increasing demand for organized healthcare services provide a favorable backdrop, despite challenges such as rising operational costs and regulatory shifts. Over the next 12-24 months, key opportunities include leveraging new capacities and enhancing digital services, while watchpoints include the successful integration of acquisitions and potential impacts from regulatory changes. Overall, Max Healthcare is positioned for long-term growth, with a target price reflecting an expected upside of approximately 20.6%
Why We Like This Stock
- Aggressive capacity expansion with a pipeline of over 4,000 new beds enhances revenue potential
- Successful integration of Kalinga Hospital strengthens market position in Eastern India
- Stable pricing power in the healthcare sector supports revenue growth amidst operational challenges
Things To Watch Out For
- Short-term margin pressures due to new capacity commissioning and rising operational costs
- Potential regulatory shifts could impact future profitability and operational efficiency
- Declining revenue share from oncology may affect overall financial performance in the near term
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 5,406 | 7,028 | 8,373 | 8,816 | 10,580 |
| Profit Before Tax (Cr.) | 1,365 | 1,479 | 1,724 | 1,794 | 2,228 |
| PBT Margin | 25.2% | 21.0% | 2059.0% | 20.3% | 21.1% |
| Net Profit (Cr.) | 1,094 | 1,126 | 1,506 | 1,566 | 1,945 |
| Earnings Per Share | 11.2 | 11.6 | 15.5 | 16.1 | 20.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| CLSA | ▲ Outperform | 1,160 | 17-Aug-2026 |
| Choice Equity | ► Hold | 1,160 | 03-Jun-2026 |
| Citigroup | ▲ Buy | 1,240 | 17-Aug-2026 |
| Goldman Sachs | ▲ Buy | 1,300 | 13-Apr-2026 |
| HDFC Securities | ► Add | 1,140 | 25-May-2026 |
| HSBC | ▲ Buy | 1,125 | 09-Jun-2026 |
| ICICI Securities | ▲ Buy | 1,275 | 17-Aug-2026 |
| JPMorgan | ▲ Overweight | 1,300 | 17-Aug-2026 |
| Jeffries | ▲ Buy | 1,260 | 17-Aug-2026 |
| Kotak Securities | ▼ Sell | 975 | 06-Jun-2026 |
| Moneycontrol | ▼ Underweight | nan | 17-Aug-2026 |
| Prabhudas Liladhar | ▲ Buy | 1,150 | 17-Aug-2026 |
| UBS | ▲ Buy | 1,300 | 17-Aug-2026 |
Company Overview
Show Company Profile
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, gynecology, pediatrics, and nephrology, liver and biliary sciences, gastroenterology and Gi surgery, plastic and reconstructive surgery, and organ transplants, as well as ear, nose, and throat. The company also provides Max@Home, a platform that offers health and wellness services at home; and MaxLab, which provides diagnostic services to patients outside its network of hospitals through various channels comprising third-party hospital laboratory management. It operates through a network of healthcare facilities, including hospitals and medical centres. The company was incorporated in 2001 and is based in Gurugram, India.